OCRELIZUMAB IN THE TREATMENT OF PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS

by E. V. Popova
Published 2018-02-01

Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker

by Shannon Kolind, Arshia Seddigh, Anna Combes, Bretta Russell-Schulz, Roger Tam, Vignan Yogendrakumar, Sean Deoni, Naomi A. Sibtain, Anthony Traboulsee, Steven C.R. Williams, Gareth J. Barker, Peter A. Brex
Published 2015-01-01

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle

by Ahmed Abdelhak, Martin S. Weber, Martin S. Weber, Hayrettin Tumani, Hayrettin Tumani
Published 2017-05-01

The Role of B Cells in Primary Progressive Multiple Sclerosis

by Jameson P. Holloman, Robert C. Axtell, Robert C. Axtell, Nancy L. Monson, Nancy L. Monson, Gregory F. Wu, Gregory F. Wu
Published 2021-06-01

Features of the visual analyzer change in the primary progressive type of multiple sclerosis

by E. E. Ioileva, M. S. Krivosheeva
Published 2019-06-01

Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis

by A. N. Boyko, M. V. Davydovskaya, N. V. Khachanova, M. N. Zakharova, N. N. Spirin, E. V. Popova, V. M. Alifirova, Ya. V. Vlasov, S. A. Sivertseva, F. A. Khabirov, M. V. Shumilina, E. P. Evdoshenko
Published 2019-11-01

Gray Matter Matters: A Longitudinal Magnetic Resonance Voxel-Based Morphometry Study of Primary Progressive Multiple Sclerosis

by Ted L. Rothstein
Published 2020-11-01

Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?

by Ahmed Abdelhak, Andreas Junker, Johannes Brettschneider, Jan Kassubek, Albert C. Ludolph, Markus Otto, Hayrettin Tumani
Published 2015-07-01

Natural course of multiple sclerosis in the first five years of the disease in the Kujawsko-Pomorskie district

by Łukasz Rzepiński, Sławomir Wawrzyniak, Małgorzata Rzepińska
Published 2016-03-01

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis

by Francisco Carlos Pérez‐Miralles, Daniel Prefasi, Antonio García‐Merino, José Ramón Ara, Guillermo Izquierdo, Virginia Meca‐Lallana, Francisco Gascón‐Giménez, María Luisa Martínez‐Ginés, Lluis Ramió‐Torrentà, Lucienne Costa‐Frossard, Óscar Fernández, Sara Moreno‐García, Jorge Maurino, Joan Carreres‐Polo, Bonaventura Casanova
Published 2021-04-01

Validation of Quantitative Scores Derived From Motor Evoked Potentials in the Assessment of Primary Progressive Multiple Sclerosis: A Longitudinal Study

by Martin Hardmeier, Christian Schindler, Jens Kuhle, Peter Fuhr
Published 2020-07-01

Ocrelizumab in treatment of primary-progressive multiple sclerosis: systematic review

by D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, E. M. Olyushina, K. I. Polyakova, A. G. Fisun, M. G. Grinin, K. A. Kokushkin
Published 2018-07-01

The experience of using ocrelizumab in routine practice

by E. V. Popova, S. A. Ryabov
Published 2020-03-01

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

by Vermersch Patrick, Benrabah Rabah, Schmidt Nicolas, Zéphir Hélène, Clavelou Pierre, Vongsouthi Cyrille, Dubreuil Patrice, Moussy Alain, Hermine Olivier
Published 2012-06-01

Alterations in Sensorimotor and Mesiotemporal Cortices and Diffuse White Matter Changes in Primary Progressive Multiple Sclerosis Detected by Adiabatic Relaxometry

by Pavel Filip, Pavel Filip, Michal Dufek, Silvia Mangia, Shalom Michaeli, Martin Bareš, Martin Bareš, Daniel Schwarz, Daniel Schwarz, Ivan Rektor, Lubomír Vojtíšek
Published 2021-09-01

CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration

by Marc Pawlitzki, Marc Pawlitzki, Stefanie Schreiber, Stefanie Schreiber, Daniel Bittner, Daniel Bittner, Julia Kreipe, Frank Leypoldt, Klemens Rupprecht, Roxana O. Carare, Sven G. Meuth, Stefan Vielhaber, Stefan Vielhaber, Peter Körtvélyessy, Peter Körtvélyessy, Peter Körtvélyessy, Peter Körtvélyessy
Published 2018-12-01

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE...

by Petra Dirks, Vera Zingler, Jost Leemhuis, Heike Berthold, Stefanie Hieke-Schulz, David Wormser, Tjalf Ziemssen
Published 2020-03-01

Linear Modeling of Multiple Sclerosis and Its Subgroubs

by Yeliz Karaca, Onur Osman, Rana Karabudak
Published 2015-03-01

Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis

by Tilman Robinson, Ahmed Abdelhak, Tanima Bose, Edgar Meinl, Markus Otto, Uwe K. Zettl, Rick Dersch, Hayrettin Tumani, Sebastian Rauer, André Huss
Published 2020-11-01